Key result
Intratumoral inoculation of the intergeneric poliovirus recombinant PV1(RIPO) resulted in an 88% survival rate at 50 days and eliminated established intracerebral glioma xenografts in athymic mice.
Why the study?
Does PV1(RIPO) reduce tumor growth and improve survival in athymic mice with malignant glioma xenografts?
Does PV1(RIPO) reduce tumor growth and improve survival in athymic mice with malignant glioma xenografts?
Highly attenuated poliovirus recombinants demonstrate strong oncolytic potential against malignant gliomas in preclinical models, suggesting their potential as biotherapeutic antineoplastic agents.
Answers are grounded in this paper and cite their sources.
Supports oncolytic PV1(RIPO) development in glioma models; leaves open human safety and efficacy trials.
Poliovirus neuropathogenicity depends on sequences within the 5' nontranslated region of the virus. Exchange of the poliovirus internal ribosomal entry site with its counterpart from human rhinovirus type 2 resulted in attenuation of neurovirulence in primates. Despite deficient virus propagation in cells of neuronal origin, nonpathogenic polio recombinants retain excellent growth characteristics in cell lines derived from glial neoplasms. Susceptibility of malignant glioma cells to poliovirus may be mediated by expression of a poliovirus receptor, CD155, in glial neoplasms. Intergeneric polio recombinants with heterologous internal ribosomal entry site elements unfolded strong oncolytic potential against experimentally induced gliomas in athymic mice. Our observations suggest that highly attenuated poliovirus recombinants may have applicability as biotherapeutic antineoplastic agents.
No takes yet. Share an insight, caveat, or question.
Gromeier et al. (2000) studied Malignant glioma. PV1(RIPO) (intergeneric poliovirus recombinant) vs. PBS or untreated was evaluated on Survival at 50 days (intracerebral xenograft model). Intratumoral inoculation of the intergeneric poliovirus recombinant PV1(RIPO) resulted in an 88% survival rate at 50 days and eliminated established intracerebral glioma xenografts in athymic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: